Targeting the transferrin receptor for brain drug delivery

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)Forskningpeer review

1 Citation (Scopus)

Resumé

Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear clinical potential.

OriginalsprogEngelsk
Artikelnummer101665
TidsskriftProgress in Neurobiology
Vol/bind181
ISSN0301-0082
DOI
StatusUdgivet - 1 okt. 2019

Fingerprint

Transferrin Receptors
Blood-Brain Barrier
Brain
Pharmaceutical Preparations
Nanomedicine
Central Nervous System Diseases
Food
Membranes

Bibliografisk note

Copyright © 2019 Elsevier Ltd. All rights reserved.

Citer dette

@article{0d74f0c77e0a402eae8d67345ea0c5a5,
title = "Targeting the transferrin receptor for brain drug delivery",
abstract = "Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear clinical potential.",
keywords = "Antibody, Brain drug delivery, Nanoparticle, Transcytosis, Transferrin receptor",
author = "{Bendix Johnsen}, Kasper and Annette Burkhart and {Bohn Thomsen}, Louiza and Andresen, {Thomas Lars} and Torben Moos",
note = "Copyright {\circledC} 2019 Elsevier Ltd. All rights reserved.",
year = "2019",
month = "10",
day = "1",
doi = "10.1016/j.pneurobio.2019.101665",
language = "English",
volume = "181",
journal = "Progress in Neurobiology",
issn = "0301-0082",
publisher = "Pergamon Press",

}

Targeting the transferrin receptor for brain drug delivery. / Bendix Johnsen, Kasper; Burkhart, Annette; Bohn Thomsen, Louiza; Andresen, Thomas Lars; Moos, Torben.

I: Progress in Neurobiology, Bind 181, 101665, 01.10.2019.

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)Forskningpeer review

TY - JOUR

T1 - Targeting the transferrin receptor for brain drug delivery

AU - Bendix Johnsen, Kasper

AU - Burkhart, Annette

AU - Bohn Thomsen, Louiza

AU - Andresen, Thomas Lars

AU - Moos, Torben

N1 - Copyright © 2019 Elsevier Ltd. All rights reserved.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear clinical potential.

AB - Obtaining efficient drug delivery to the brain remains the biggest challenge for the development of therapeutics to treat diseases of the central nervous system. The main obstacle is the blood-brain barrier (BBB), which impedes the entrance of most molecules present in the systemic circulation, especially large molecule drugs and nanomedicines. To overcome this obstacle, targeting strategies binding to nutrient receptors present at the luminal membrane of the BBB are frequently employed. Amongst the numerous potential targets at the BBB, the transferrin receptor (TfR) remains the most common target used to ensure sufficient drug delivery to the brain. In this review, we provide a full account on the use of the TfR as a target for brain drug delivery by describing the function of the TfR in the BBB, the historical background of its use in drug delivery, and the most recent evidence suggesting TfR-targeted medicines to be efficient for brain drug delivery with a clear clinical potential.

KW - Antibody

KW - Brain drug delivery

KW - Nanoparticle

KW - Transcytosis

KW - Transferrin receptor

UR - http://www.scopus.com/inward/record.url?scp=85070401494&partnerID=8YFLogxK

U2 - 10.1016/j.pneurobio.2019.101665

DO - 10.1016/j.pneurobio.2019.101665

M3 - Review article

VL - 181

JO - Progress in Neurobiology

JF - Progress in Neurobiology

SN - 0301-0082

M1 - 101665

ER -